Compare Adaptive Biotechnologies Corp (ADPT) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs DigitalOcean Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while DigitalOcean Holdings Inc trades at $123.5 (market cap $15.25B). The key difference: DigitalOcean Holdings Inc is far larger — about 3.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | DOCN | |
|---|---|---|
Market Cap | $4.05B | $15.25B |
Sector | Health | Technology |
52-Week High | $25.45 | $181.29 |
52-Week Low | $12.30 | $29.99 |
Enterprise Value | $4.12B | $16.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
DigitalOcean (DOCN) trades at $124.15, up 1.57% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with 29% revenue growth driven by AI demand, and raised full-year guidance. Valuation ratios are elevated, with a P/E of 56.43 and P/S of 13.99, reflecting high growth expectations. Analyst consensus is bullish with a $173.71 price target, though net cash flow turned negative in 2025 due to investing activities.
Outlook is positive given accelerating AI-driven revenue growth and profitability, but risks include high debt levels, competitive cloud market pressures, and stretched valuations. The stock offers upside if execution continues, but investors face volatility from earnings sensitivity and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
